| NCT Number | NCT07292233 |
| Lead Sponsor | Luye Pharma Group Ltd. |
| Conditions | Schizophrenia, Alzheimer's Disease Psychosis |
| Enrollment | 16 participants |
| Start Date | 2025-07-30 |
| Primary Completion | 2025-08-27 (estimated) |
| Study Completion | 2026-03-30 (estimated) |
| Updated on ClinicalTrials.gov | 2025-12-18 |